ArticleVaccines2023

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses.

Lorena Usero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.